

บรรณานุกรม

- กรมวิทยาศาสตร์การแพทย์. Manual. Pathogens. หลักเกณฑ์ในการเลือกเชื้อเพื่อเฝ้าระวังการดื้อยาต้านจุลชีพ. ศูนย์เฝ้าระวังเชื้อดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[4 screens]. Available from : URL: <http://narst.dmsc.moph.go.th/ars/manual1.html>
- กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from North region of Thailand 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL: http://narst.dmsc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=nor&action=submit
- กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from South region of Thailand 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL:- http://narst.dmsc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=sou&action=submit
- กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from Northeast region of Thailand 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL:http://narst.dmsc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=noe&action=submit
- กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from East region of Thailand 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL: http://narst.dmsc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=est&action=submit
- กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from Central region of Thailand 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL: http://narst.dmsc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=cen&action=submit

กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from Bangkok 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL: http://narst.dmhc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=ban&action=submit

กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Top ten pathogen recovered from blood in patients from Thailand 2001. ศูนย์เฝ้าระวังการดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[1 screen]. Available from : URL: http://narst.dmhc.moph.go.th/a5.php?SPEC_DATE=2001&SPEC_TYPE=bl&PLACE=all&action=submit

กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Antibiogram 1998. ศูนย์เฝ้าระวังเชื้อดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[2 screens]. Available from : URL: <http://narst.dmhc.moph.go.th/ars/box/anti1998.htm>

กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Antibiogram 1999. ศูนย์เฝ้าระวังเชื้อดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[2 screens]. Available from : URL: <http://narst.dmhc.moph.go.th/ars/box/anti1999.htm>

กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Antibiogram 2000. ศูนย์เฝ้าระวังเชื้อดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[2 screens]. Available from : URL: <http://narst.dmhc.moph.go.th/ars/box/anti2000.htm>

กรมวิทยาศาสตร์การแพทย์. Result of antimicrobial resistance surveillance. Antibiogram 2001. ศูนย์เฝ้าระวังเชื้อดื้อยาแห่งชาติ [serial online][cited 2002 Jun 2]:[2 screens]. Available from : URL: <http://narst.dmhc.moph.go.th/ars/box/anti2001.htm>

กลุ่มงานพยาธิวิทยาคลินิก โรงพยาบาลสงขลานครินทร์. ความไวของแบคทีเรียต่อยาต้านจุลชีพ โรงพยาบาลสงขลานครินทร์ 2542., สงขลา. 2542.

กลุ่มงานพยาธิวิทยาคลินิก โรงพยาบาลสุราษฎร์ธานี. Percentage of susceptible organisms 2002., สุราษฎร์ธานี. 2542.

กลุ่มงานพยาธิวิทยาคลินิก โรงพยาบาลมหาราชนครเชียงใหม่. Percentage of susceptible organisms frequently isolated from blood., เชียงใหม่. 2003.

กลุ่มงานพยาธิวิทยาคลินิก โรงพยาบาลมหาราชนครเชียงใหม่. Percentage of susceptible organisms frequently isolated from all clinical specimens., เชียงใหม่. 2004.

- กลุ่มงานพยาธิวิทยาคลินิก โรงพยาบาลมหาสารนครศรีธรรมราช. ความไวของแบคทีเรียต่อยาต้านจุลชีพ โรงพยาบาลมหาสารนครศรีธรรมราช 2541., นครศรีธรรมราช. 2541.
- เพชรน้อย สິงห์ช่างชัย สถิตินื้อนพารามตริกเพื่อการวิจัยทางการพยาบาล. สงขลา : คณะพยาบาลศาสตร์ มหาวิทยาลัยสงขลานครินทร์.
- เต็มศรี ชำนิจารกิจ. สถิติประยุกต์ทางการแพทย์. กรุงเทพมหานคร: คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย.
- ทัตสนี นุชประยูร, และเต็มศรี ชำนิจารกิจ. สถิติในวิจัยทางการแพทย์. กรุงเทพมหานคร:จุฬาลงกรณ์มหาวิทยาลัย,2541.
- ระพีพรรณ ฉลองสุข. สถิติสำหรับเภสัชกร: การวิเคราะห์ข้อมูล. กรุงเทพมหานคร: คณะเภสัชศาสตร์ มหาวิทยาลัยศิลปากร, 2543.
- วีระศักดิ์ จงสู่วิวัฒน์วงศ์. กราฟ ตาราง และสมการสำหรับการวิจัยทางสุขภาพ. กรุงเทพมหานคร: คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์.
- สังวาลย์ รักษ์เผ่า. ระเบียบวิธีวิจัยและสถิติในการวิจัยทางคลินิก. เชียงใหม่: คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่, 2538.
- Ariffin H, Navaratmam P, Mohamed M, et al. Ceftazidime-resistant *Klebsiella pneumoniae* bloodstream infection in children with febrile neutropenia. *Int J infect Dis* 1999;4:21–5.
- Aswapokee N, Pruksachatvuthi S, Charoensook B. Prevalence and susceptibility pattern of bacteria producing extended spectrum β -lactamases in a university hospital. *J Infect Dis Antimicro Agents* 1994;11:49-53.
- Babini GS, Livermore DM. Antimicrobial resistance amongst *Klebsiella spp.* collected from intensive care units in Southern and Western Europe in 1997–1998. *J Antimicrob Chemother* 2000;45:183–9.
- Ball P. The quinolones: history and overview. Gootz TD and Brighty KE. Chemistry and mechanism of action of the quinolone antimicrobials. Kohler T and Pechere JC. Bacterial resistance to quinilones: mechanisms and clinical implications. Andriole VT. The quinolones: products. In Andriole VT. The quinolones. 2nd edition. Academic Press. 1998 San Diego.

- Bauernfeind A, Stemplinger I, Jungwirth R, et al. Characterization of β -lactamase gene *bla*_{PER-2}, which encodes an extended-spectrum class A β -lactamases. *Antimicrob Agents Chemother* 1996;40:616-20.
- Beringer A. Therapeutic challenges associated with extended spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *Pharmacotherapy* 2001;21:583-92.
- Bonnet R, Sampaio JL, Labia R, et al. A novel CTX-M β -lactamase (CTX-M-8) in cefotaxime-resistant *Enterobacteriaceae* isolated in Brazil. *Antimicrob Agents Chemother* 2000;44: 1936-42.
- Bradford PA. Extended spectrum β -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 2001;48: 933-51.
- Bradford PA, Cherubin CE, Idemyor V, et al. Multiply resistant *Klebsiella pneumoniae* strains from two Chicago Hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β -lactamases in a single isolate. *Antimicrob Agents Chemother* 1994;38:761-6.
- Bradford PA, Urban C, Mariano N, et al. SHV-7, a novel cefotaxime- hydrolyzing β -lactamases, identified in *Escherichai coli* isolates from hospitalized nursing home patients. *Antimicrob Agents Chemother* 1995;39:899-905.
- Bradford PA, Urban C, Mariano N, et al. Imipenem resistance in *Klebsiella pneumoniae* is associated with combination of ACT-1, a plasmid-mediated Amp C β -lactamase and the loss of an outer membrane protein. *Antimicrob Agents Chemother* 1997;41:563-9.
- Bret L, Chanel C, Sirot D, et al. Characterization of an inhibitor-resistant enzyme IRT-2 devired from TEM-2 β -lactamases produced by *Proteus mirabilis* strain. *J Antimicrob Chemother* 1996;38:183-91.
- Brun-Buisson C, Legrand P, Philippon A, et al. Transferable enzymatic resistance to third generation cephalosporins during nosocomial outbreak of multiresistant *Klebsiella pneumoniae*. *Lancet* 1987;2:302-6.

- Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* 1995;39:1211–33.
- Branger C, Lesimple CA, Bruncu B, et al. Long-term investigation of the clonal dissemination of *Klebsiella pneumoniae* isolates producing extended spectrum β -lactamases in a university hospital. *J Med Microbiol* 1998;47:201-9.
- Chaibi EB, Sirot D, Paul G, et al. Inhibitor-resistant TEM β -lactamases: phenotypic, genetic and biochemical characteristics. *J Antimicrob Chemother* 1999;43:447-58.
- Chanawong A, Zali FH, Heritage J, et al. SHV-12,SHV-5,SHV-2a and VEB-1 extended-spectrum β -lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. *J Antimicrob Chemother* 2001;48:839-52.
- Cormican MG, Marshall SA, Jones RN. Detection of extended spectrum β -lactamase (ESBL)-producing by the E-test ESBL screen. *J Clin Microbiol* 1996;34:1880–4.
- Cotton MF, Wasserman E, Pieper CH. Invasive disease due to extended spectrum β -lactamase producing *Klebsiella pneumoniae* in a neonatal unit: the possible role of cockroaches. *J Hosp Infect* 2000;44:13–7.
- Danel F, Hall LC, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β -lactamase, isolated from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1999;43:1362-6.
- Dawis M, Isenberg H, France K, et al. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. *J antimicrob Chemother* 2003;51:1203-11.
- Dejsirilert S, Apisarnthanarak A, Kijphati R, et al. The status of antimicrobial resistance in Thailand among gram-negative pathogens bloodstream infection: NARST DATA, 2000-2003. 9th Western Pacific Congress on Chemotherapy and Infectious diseases., abstr. FP-A-3, 2004.
- Doucet-Populaire F, Ghnassia JC, Bonnet R, Sirot J. First isolation of a CTX-M-3-producing *Enterobacter cloacae* in France. *Antimicrob Agents Chemother* 2000;44:3239-40.

- Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infection: risk factors and clinical outcome. *Intensive Care Med* 2002;28:1718–23.
- Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of *Acinetobacter* infections sensitive only to polymixin B and sulbactam. *Lancet* 1994;344:1329–32.
- Emery CL, Weymouth LA. Detection and clinical significance of extended spectrum β -lactamases in a tertiary care medical center. *J Clin Microbiol* 1997;35:2061–7.
- Ena J, Lopez-perezagua M, Martinez-peinado C, et al. Emergence of ciprofloxacin resistance in *Escherichia coli* isolates after widespread use of fluoroquinolones. *Diagn Microbiol Infect Dis* 1998;30:103–7.
- Hollander R, Ebke M, Barck H, et al. Asymptomatic carriage of *Klebsiella pneumoniae* producing extended spectrum beta-lactamase by patients in a neurological early rehabilitation unit: management of an outbreak. *J hosp Infect* 2001;48:207–13.
- Hortivakul R. 2002. ESBL detection of Songkhanagarind hospital in 2002. Department of Medicine, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University (unpublished).
- Ingyiya N, Hortiwakul R, Chayakul P, et al. Prevalence and susceptibility patterns of *Klebsiella pneumoniae* and *Escherichia coli* producing extended-spectrum beta-lactamases in Songklanagarind Hospital, Thailand. *J Infect Dis Antimicrob Agents* 2003;20:127–34.
- Jacoby GA, Medeiros AA, O' Brien TF, Pinto ME, Jiang J. Broad-spectrum transmissible β -lactamase. *N Eng J Med* 1989;319:723–4.
- Jacoby GA, Medeiros AA. More extended spectrum β -lactamases. *Antimicrob Agents Chemother* 1991;35:1697–704.
- Jackson JJ, Kropp H. β -lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP)2-specific imipenem and PBP3-specific ceftazidime. *J Infect Dis* 1992;65:1033–41.
- Jai A, Roy I, Gupta MK, et al. Prevalence of extended-spectrum β -lactamases producing gram-negative bacteria in septicemic neonates in a tertiary care hospital. *J Med Microbiol* 2003; 52:421–5.

- Jones RN, Summation: β -Lactam resistance surveillance in the Asia-western pacific region. *Diagn Microbiol Infect Dis* 1999;35:333-8.
- Kang CI, Kim AH, Kim DM, et al., Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamases producing *Klebsiella pneumoniae*. *Control Hosp Epidemiol* 2004;25:860-7.
- Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended-spectrum betalactamases. *J Antimicrob Chemother* 1996;37:203-4.
- Kim YK, Pai H, Lee H, et al. Bloodstream infections by extended. spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Children: epidemiology and clinical outcome. *Antimicrob Agents Chemother* 2002;46:1481-91.
- Knothe H, Shah P, Kremery V, Antal M and Mitsuhasshi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection* 1983;11:315-7.
- Kusum M, Wongwanich S, Dhiraputra C, et al. Occurrence of Extended spectrum β -lactamases in clinical isolates of *Klebsiella pneumoniae* in a university hospital, Thailand. *J Med Assoc Thai* 2004;87:1029-33.
- Lautenbach E, Potel JB, Biker WB, et al. Extended spectrum β -lactamases producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact on resistance of outcomes. *Clin Infect Dis* 2001;32:1162-71.
- Lautenbach E, Strom B, Bilker W. et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *Cline Infect Dis* 2001;1288-94.
- Lemozy J, Sirot D, Channal C, et al. First characterization of inhibitor-resistant enzyme TEM (IRT) β -lactamase in *Klebsiella pneumoniae* strain. *Antimicrob Agents Chemother* 1995; 33:2580-2.
- Livermore DM. β -lactamase-mediated resistance and opportunities for its control. *J Antimicrob Chemother* 1998;41(suppl D):25-41.
- Livermore DM, Struelens M, Amorin J, et al. Multicentre evaluation of Vitek 2 advanced expert system for interpretive reading of antimicrobial resistance tests. *J Antimicrob Chemother* 2002;49:289-300.

- Mackenzie FM, Forbes KJ, Dorai-John T, et al. Emergence of a carbapenem-resistant *Klebsiella pneumoniae* [letter]. *Lancet* 1997;350:783.
- Macrac MB, Shannon KP, Rayner DM, et al. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant *Klebsiella pneumoniae* controllable only by ward closure. *J Hosp Infect* 2001;49:183-92.
- Mahon CR, Manuselis G. Textbook of diagnostics microbiology. W.B. Saunders company. 1995 Philadelphia.
- Martinez-Martinea L, Hernandez-Alles S, Alberi S, et al. In vivo selection of porin-deficient mutants of *Klebsiella pneumoniae* with increased resistance to ceftazidime and expanded-spectrum cephalosporins. *Antimicrob Agents Chemother* 1996;40:342-8.
- Martinez-Martinez L, Jacoby GA. Quinolone resistance from a transferable plasmid. *Lancet* 1998;351:797-9.
- Masuda N, Ohya S. Cross-resistance to meropenem, cephems and quinolones in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1992;36:1847-51.
- Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of *Klebsiella* infection resistant to late-generation cephalosporins. *Ann Intern Med* 1993;119:353-8.
- Medeiros AA. Evolution and dissemination of β -lactamases accelerated by generations of β -lactamases accelerated by generations of β -lactam antibiotics. *Clin Infect Dis* 1997;24: S19-45.
- Meyer KS, Urban C, Eagan J A, et al. Nosocomial outbreak of *Klebsiella* infection resistant to late-generation cephalosporins. *Ann Intern Med* 1993;119:353-8.
- Mugnier P, Dubrous P, Casin I, et al. A TEM-derived extend-spectrum β -lactamases in *Pseudomonase aeroginisa*. *Antimicrob Agent Chemother* 1996;40:2488-93.
- Nathisuwan S, Burgess D, lewiss II J. Extended spectrum β -lactamases: epidemiology, detection, and treatment. *Pharmacotherapy* 2001;21:920-8.
- National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5 and informational supplement M100-S12. Wayne (PA): National Committee for Clinical Laboratory Standards 2000.

- National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing, 11 th supplement. M100-S11, vol. 21, no. 1. Wayne (PA): National Committee for Clinical Laboratory Standards, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5 and informational supplement M100-S12. Wayne (PA): 2001.
- Naumovski L, Quinn JP, Miyashiro D et al. Outbreak of ceftazidime resistance due to a novel extended spectrum β -lactamase in isolates from cancer patients. *Antimicrob Agents Chemother* 1992;36:1991-6.
- Pai H. The characteristics of extended spectrum β -lactamases in Korea isolates of *Enterobacteriaceae*. *Yonsei Med J* 1998;39:514-9.
- Pai H, Choi E, Lee H, et al. Identification of CTX-M-14 extended spectrum β -lactamase in clinical isolates of *Shigella sonnei*, *Escherichia coli* and *Klebsiella pneumoniae* in Korea. *J Clin Microbiol* 2001;39:3747-9.
- Pangon B, Bizet C, Bure F, et al. In vivo selection of a cephamycin-resistant porin-deficient mutant of *Klebsiella pneumoniae* producing a TEM-3 β -lactamase. *J Infect Dis* 1989;159: 1005-6.
- Perterson DL, Ko WC, Mohapatra S, et al. Abstr. 37th Intersci. Conf. Antimicrob. Agent Chemother., abstr. J-210,1997.
- Perterson DL, Ko WC, Gottberg AV, et al. Abstr. 36th Annu. Meet. Infect. Dis.Soc. Am., abstr. 188,1998.
- Paterson DL, Ko W, Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β -lactamase: implications for the clinical microbiology laboratory. *J Clin Microbiol* 2001;39:2206-12.
- Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended spectrum β -lactamase producing in *Klebsiella pneumoniae*. *Clin Infect Dis* 2000;30:473-8.
- Paterson DL, Singh N, Gayowski T, Marino IR. Fatal infection due to extended spectrum β -lactamase-producing *Escherichia coli*: implications for antibiotic choice for spontaneous bacterial peritonitis. *Clin Infect Dis* 1999;28:683-4.

- Paterson D, Singh N, Rihs JD, et al. Control of an outbreak of infection due to extended spectrum beta-lactamase-producing *Escherichia coli* in a liver transplantation unit. *Clin Infect Dis* 2001;33:126–8.
- Pattharachayakul S, et al. Extended-spectrum β -lactamase (ESBL)-producing *Klebsiella pneumoniae*: activity of single versus combination agents. *J Antimicrob Chemother* 2003;51: 737–9.
- Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to *Klebsiella pneumoniae* producing extended spectrum β -lactamases. *Antimicrob Agents Chemother* 1998;42:53–8.
- Pena C, Pujol M, Ardanuy C, et al. An outbreak of hospital-acquired *Klebsiella pneumoniae* bacteraemia, including strains producing extended spectrum β -lactamase. *J Hosp Infect* 2001;47:53–9.
- Pfaller MA, Jones RN, Doern GV, et al. Multicenter evaluation of antimicrobial resistance to six broad spectrum β -lactams in Colombia: comparison of data from 1997 and 1998 using the E test method. *Diagn Microbiol Infect Dis* 1999;35:235–41.
- Philippou LN, Naas T, Bouthors A-T, Barakett V, Nordmann P. OXA-18,a class D clavulanic acid-inhibited extended-spectrum β -lactamase from *Pseudomonase aeruginosa*. *Antimicrob Agents Chemother* 1997;41:2188-95.
- Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β -lactamase encoded by an *Escherichia coli* integron gene. *Antimicrob Agents Chemother* 1999;43:573-81.
- Piroth L, Aube H, Doise JM and Vincent-Martin M. Spread of extended-spectrum β -lactamase-producing *Klebsiella pneumoniae*: Are β -lactamase inhibitors of therapeutic value? *Clin Infect Dis* 1998;27:76-80.
- Prinarakis EE, Miriagou EV, Tzelepi E, et al. Emergence of an inhibitor-resistant β -lactamase (SHV-10) derived from SHV-5 variant. *Antimicrob Agents Chemother* 1997;41:838-40.
- Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated β -lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of *K.pneumoniae*. *Antimicrob Agents Chemother* 1989;33:1451–6.

- Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial *Klebsiella*. JAMA 1998;280:1233–7.
- Rebuck JA, Olsen KM, Fey PD, et al. In vitro activities of parenteral β -lactam antimicrobials against TEM-10, TEM-26 and SHV-5 derived extended spectrum β -lactamases expressed in an isogenic *Escherichia coli* host. J Antimicrob Chemother 2000;46:461–4.
- Rice LB, Eckstein EC, De Vente J, et al. Ceftazidime-resistant *Klebsiella pneumoniae* of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118–24.
- Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended spectrum β -lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193–9.
- Rosenau A, Cattier B, Gousset N, et al. *Capnocytophago ochracea*: characterization of a plasmid-encoded extended-spectrum TEM-17 β -lactamase in the phylum *Flavobacter-Bacteroids*. Antimicrob Agents Chemother 2000;44:760-2.
- Rupp M, Fey P. Extended spectrum β -lactamase (ESBL)-producing *Enterobacteriaceae*: considerations, prevention and drug treatment. Drug 2003;63:353–65.
- Sabate M, Tarrago R, Navarro F, et al. Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing β -lactamase (CTX-M-9) from *Escherichia coli* in Spain. Antimicrob Agents Chemother 2000;44:1970-3.
- Salyers AA, Whitt DD. Bacterial pathogenesis: a molecular approach. ASM Press. 1994 Washington DC.
- Sanders CC, Barry AL, Washington JA, et al. Detection of extended spectrum β -lactamase-producing members of the family *Enterobacteriaceae* with the Vitek ESBL test. J Clin Microbiol 1996;34:2997–3001.
- Sanders CC, Peyret M, Moland ES, et al. Ability of VITEX 2 advanced expert system to identify β -lactam phenotypes in isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa*. J Clin Microbiol 2000;38:570–4.
- Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime resistant *K.pneumoniae* and *Escherichia coli* bloodstream infection: a case control and molecular epidemiologic investigation. J Infect Dis 1996;174:529–36.

- Sirot D, Sirot J, Labia R, et al. Transferable resistance to third-generation cephalosporins in clinical isolates of *K.pneumoniae*: identification of CTX-1, a novel β -lactamase. *J Antimicrob Chemother* 1987;20:323-34.
- Sirot D, Recule EB, Chaibi L, et al. A complex mutant of TEM-1 β -lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by *Escherichia coli* clinical isolate. *Antimicrob Agents Chemother* 1997;41:1322-5.
- Siu LK, Lu PL, Hsueh PR, et al. Bacteremia due to extended-spectrum β -lactamase-pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. *J Clin Microbiol* 1999;40:20-7.
- Sookpranee T, Tattawasart U, Sookpranee M. Ceftazidime resistant *Klebsiella pneumoniae* in Srinagarind hospital, possessing uniquely new extended-spectrum beta-lactamase. *J Infect Dis Antimicrob Agents* 1993;10:77-81.
- Spanu T, Luzzaro F, perilli M, et al. The Italian ESBL Study Group. Occurrence of extended spectrum β -lactamases in members of the family *Enterobacteriaceae* in Italy: implications for resistance to β -lactams and other antimicrobial drugs. *Antimicrob Agents Chemother* 2002;46:196-202.
- Stapleton PD, Shannon KP, French GL. Carbapenem resistance *Escherichia coli* associated with plasmid-determined CMY-4 β -lactamase production and loss of an outer membrane protein *Antimicrob Agents Chemother* 1999;43:1206-10.
- Steward CD, Rasheed JK, Hubert SK, et al. Characterization of clinical isolates of *Klebsiella pneumoniae* from 19 laboratories using the National Committee for Clinical Laboratory Standards extended spectrum β -lactamases detection methods. *J Clinical Microbiol* 2001;39:2864-72.
- Stobberingh EE, Arends J, Hoogkamp-Korstanje JA, et al. Occurrence of extended spectrum β -lactamases in Dutch hospitals. *Infection* 1999;27:348-54.
- Teangrem S. 2002. Microbiology. Extended-spectrum beta-lactamase, ESBL. Thailand Infectious Diseases Association. [serial online][cited 2003 Nov 25];[5 screens]. Available from : URL: <http://idthai.org/Download/Microbiology/ESBL.pdf>.

- Tenover FC, Mohammed MJ, Gorton TS, et al. Detection and reporting of organisms producing extended spectrum beta-lactamases: survey of laboratories in Connecticut. *J Clin Microbiol* 1999;37:4035-70.
- Thauvin C, Tripodi M, Moellering R, et al. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended spectrum β -lactamase-producing strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 1997;41:1053-7.
- Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam and the inoculum effect in tests with extended spectrum beta-lactamase-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* 2001;45:3548-54.
- Thomson KS, Sanders CC. Detection of extended-spectrum β -lactamases in members of the family *Enterobacteriaceae*: comparison of the double-disk and three-dimensional tests. *Antimicrob Agents Chemother* 1992;36:1877-82.
- Vahaboglu H, Ozturk R, Aygun G, et al. Widespread detection of PER-1-type extended spectrum β -lactamase among nosocomial *Acinetobacter* and *Pseudomonase aeruginosa* in Turkey: a nationwide multicenter study. *Antimicrob Agents Chemother* 1997;41:2265-9.
- Vercauteren E, Descheemaeker P, Leven M, et al. Comparison of screening methods for detection of extended spectrum β -lactamase and their prevalence among blood isolates of *Escherichia coli* and *Klebsiella spp*. In a Belgian Teaching Hospital. *J Clin Microbiol* 1997;35:2191-7.
- Vila JM, Navia M, Ruiz J, et al. Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived β -lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 1997;41:2757-9.
- Weiner J, Quinn JP, Bradford PA, et al. Multiple antibiotic resistant *Klebsiella* and *Escherichia coli* in nursing homes. *JAMA* 1999;281:517-23.
- Xiong S, Shu D, Wang F, et al. Investigation of extended spectrum β -lactamase in *Klebsiellae pneumoniae* and *Escherichia coli* from China. *Diagn Microbiol Infect Dis* 2002;44:195-200.

- Yan JJ, Wu SM, Tsai SH, et al. Prevalence of SHV-12 among clinical isolates of *Klebsiellae pneumoniae* producing extended spectrum beta-lactamase and identification of a novel Amp-C enzyme (CMY-8) in southern Taiwan. *Antimicrob Agents Chemother* 2000;44: 1438-42.
- Yang YN, Bhachech PA, Bradford BD, et al. Ceftazidime-resistant *Klebsiellae pneumoniae* and *E. coli* isolates producing TEM-10 and TEM-43 from St.Louis. *Antimicrob Agents Chemother* 1998;42:1671-6.